Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial

MLA

Akash Roy, et al. “Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial.” Journal of Clinical and Experimental Hepatology, vol. 12, Mar. 2022, pp. 336–42. EBSCOhost, https://doi.org/10.1016/j.jceh.2021.08.010.

APA

Akash Roy, Nipun Verma, Ajay Duseja, Dibya L. Praharaj, Radha K. Dhiman, Madhumita Premkumar, & Sunil Taneja. (2022). Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial. Journal of Clinical and Experimental Hepatology, 12, 336–342. https://doi.org/10.1016/j.jceh.2021.08.010

Chicago

Akash Roy, Nipun Verma, Ajay Duseja, Dibya L. Praharaj, Radha K. Dhiman, Madhumita Premkumar, and Sunil Taneja. 2022. “Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial.” Journal of Clinical and Experimental Hepatology 12 (March): 336–42. doi:10.1016/j.jceh.2021.08.010.